DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
QUICK SEARCH:   [advanced]


     

Drug Metabolism and Disposition Fast Forward
First published on May 30, 2007; DOI: 10.1124/dmd.106.014605

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.106.014605v1
35/9/1533    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Author home page(s):
Hristos Glavinas
Emese Kis
Akos Pal
Rita Kovacs
Marton Jani
Erika Vagi
Eva Molnar
Szava Banshagi
Gyorgy Bathori
Oliver von Richter
Gerrit-Jan Koomen
Peter Krajcsi
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Glavinas, H.
Right arrow Articles by Krajcsi, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Glavinas, H.
Right arrow Articles by Krajcsi, P.


Received for publication December 28, 2006.
Revised May 22, 2007.
Accepted for publication May 24, 2007.

ABCG2 (BCRP/MXR) ATPase assay - a useful tool to detect drug - transporter interactions

Hristos Glavinas 1, Emese Kis 1, Akos Pal 1, Rita Kovacs 1, Marton Jani 1, Erika Vagi 1, Eva Molnar 1, Szava Banshagi 1, Zoltan Kele 2, Tamas Janaky 2, Gyorgy Bathori 1, Oliver von Richter 3, Gerrit-Jan Koomen 4, Peter Krajcsi 1*

1 Solvo Biotechnology 2 University of Szeged Medical School 3 ALTANA Pharma AG 4 University of Amsterdam

* Address correspondence to: E-mail: krajcsi{at}solvo.hu

Abstract

The ATPase assay utilizing membrane preparations from recombinant baculovirus infected Sf9 cells is widely used to detect the interaction of compounds with different ABC transporters. However, Sf9 membrane preparations containing the wild type ABCG2 transporter show an elevated baseline vanadate sensitive ATPase activity, which cannot be further stimulated by substrates of ABCG2. Therefore, this assay system cannot be used for the detection of ABCG2 substrates. To overcome this difficulty i) we purified membranes from a selected human cell line expressing wild type ABCG2, and ii) inhibited the baseline ATPase activity with different inhibitors. In our modified assay ABCG2 substrates were able to stimulate the baseline ATPase activity of ABCG2 expressed in membranes of human cells. Furthermore, using the specific ABCG2 inhibitors Ko143 or Ko134 allowed us to suppress the baseline vanadate sensitive ATPase activity. Substrates of ABCG2 could stimulate this suppressed baseline ATPase resulting in a better signal-to-background ratio and a robust assay to detect substrates of the ABCG2 transporter. The ATPase assay and the direct vesicular transport measurements for estrone-3-sulfate were in good accordance.


Key words: ABC transporters, membrane transport, transporters


This article has been cited by other articles:


Home page
 In VivoHome page
M. NOWAK, J. A. MADEJ, and P. DZIEGIEL
Expression of Breast Cancer Resistance Protein (BCRP-1) in Canine Mammary Adenocarcinomas and Adenomas
In Vivo, September 1, 2009; 23(5): 705 - 709.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
E Kis, T Nagy, M Jani, E Molnar, J Janossy, O Ujhellyi, K Nemet, K Heredi-Szabo, and P Krajcsi
Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance
Ann Rheum Dis, July 1, 2009; 68(7): 1201 - 1207.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.